Metabolic monitoring for antipsychotics means establishing baselines — weight, BMI, waist circumference, blood pressure, fasting glucose or HbA1c, and a lipid profile — before the first dose, then rechecking on a fixed schedule: weight and BMI at least monthly for the first three months, then at least every three months, with glucose and lipids at baseline, 12 weeks, and annually thereafter, adjusted to risk and local guidance. The purpose is early detection: by the time glucose or lipids visibly derail a patient's health, modifiable change is much harder.

Antipsychotics are among the most metabolically consequential drugs in medicine, and the differences between agents are large enough to influence prescribing decisions. This article gives you the monitoring schedule, the risk hierarchy of individual drugs, what to do when numbers move, and the exam-facing reasoning that examiners on MRCPsych, RANZCP and USMLE-style assessments look for.

Why antipsychotics cause metabolic problems

Weight gain on antipsychotics has several overlapping mechanisms, and the drugs that cause the most of it tend to do so through the same pathways:

  • Appetite and reward signalling. H1 histamine antagonism and 5-HT2C blockade increase appetite and carbohydrate craving — the same receptor profile that makes olanzapine and clozapine so metabolically costly.
  • Insulin resistance and direct pancreatic effects. Some agents impair insulin secretion and peripheral glucose uptake independent of weight gain — glucose can deteriorate before the scale moves.
  • Sedation and reduced activity. Sedating profiles lower daily energy expenditure and worsen diet quality.
  • Lipid changes. Triglyceride rises often track with weight gain; the mechanism again links to appetite, hepatic lipogenesis and lifestyle change.

Population data puts the scale in perspective: olanzapine and clozapine produce the largest average weight gain in the first year (commonly cited figures reach several kilograms), while aripiprazole, ziprasidone and lurasidone sit at the favourable end. The ADA/APA consensus statement on antipsychotics and diabetes — now embedded in most national guidance — was written precisely because diabetes was being detected late in this population.

Metabolic monitoring for antipsychotics: the schedule

This is the core table for exams and for clinic. Frequencies below follow the common pattern in NICE NG114 and the ADA/APA-style consensus schedule — always phrase against your local guideline in practice, as exact intervals can be updated between handbook editions.

Parameter Baseline (before first dose) Ongoing frequency Notes / action thresholds
Weight / BMI Yes Weekly for first 4 weeks in high-risk starts, then at least monthly to 12 weeks, then at least quarterly ≥5% baseline weight gain at 1 month or ≥10% at any point = intervene
Waist circumference Yes Every 6–12 months (more often if weight rises) Visceral adiposity risk marker; elevated in men (e.g. ≥102 cm) or women (≥88 cm) by general criteria
Blood pressure Yes At each metabolic review Standard cardiovascular risk assessment
Glucose (fasting) or HbA1c Yes 12 weeks after starting or a significant dose change, then at least annually — sooner if weight rises Diabetes range per local criteria (e.g. HbA1c ≥48 mmol/mol / 6.5%); pre-diabetes → lifestyle + 3–6 monthly recheck
Lipids (fasting: TC, LDL, HDL, triglycerides) Yes 12 weeks, then at least annually Triglycerides often rise first; treat per standard cardiovascular risk thresholds
Prolactin (if indicated) Consider baseline for high-risk drugs (e.g. risperidone, paliperidone) Only if symptomatic Metabolic monitoring ≠ prolactin monitoring — know both schedules

The highest-yield numbers: the intervention triggers are ≥5% weight gain from baseline within the first month or ≥10% at any time — that is the point at which lifestyle intervention, metformin consideration, or a switch discussion should be happening, not at the first review.

Antipsychotic metabolic risk tiers

Not all antipsychotics are equal, and exam questions often test whether you can rank them without notes. A practical tiering (consistent with meta-analytic weight-gain data and the package-information warnings):

  • Highest risk: clozapine and olanzapine — greatest weight gain, highest rates of new-onset diabetes and dyslipidaemia. Quetiapine sits in the upper-mid range.
  • Intermediate: chlorpromazine, risperidone (moderate weight gain; prolactin issues are a separate axis), paliperidone.
  • Lower risk: aripiprazole, ziprasidone, lurasidone, brexpiprazole — meaningfully better metabolic profiles, which is why they are favoured when metabolic risk drives the choice.

Risk is not purely pharmacological. Schizophrenia itself, smoking, poor diet, reduced activity, and socioeconomic factors all contribute — and higher baseline BMI predicts larger gains. That is exactly why baseline measurement matters: without it, "stable weight" means nothing.

Exam trap

A patient has gained 8 kg over six months and the answer sheet says "start monitoring metabolic parameters." Wrong framing. Monitoring was supposed to begin before the first dose and continue on schedule — the whole point of baseline plus early fixed-interval checks is to catch drift at 5%, not diabetes at six months. If a vignette shows metabolic screening starting only after weight gain has already occurred, the flaw in care is the missing baseline and the missed early reviews, not the eventual test order.

When numbers move: what to do about it

Detection only matters if it changes management. Work through the response in tiers:

  1. Lifestyle intervention at the first 5%. Structured diet and activity support — with real follow-up, not a leaflet. Early weight gain is the most modifiable window, and it is where most services fail.
  2. Metformin as an adjunct. Reasonably evidence-supported for antipsychotic-induced weight gain, particularly when fasting glucose or HbA1c is drifting into pre-diabetic range. Check local formulary guidance.
  3. Consider a switch. If a patient on olanzapine or clozapine develops significant weight gain, dyslipidaemia or impaired glucose, weigh the metabolic gain against psychiatric stability — switching within class (e.g. to aripiprazole or lurasidone) can improve the metabolic profile but destabilise psychosis, so it is a shared decision made when the patient is well.
  4. Treat the lipids/glucose properly. Once thresholds for dyslipidaemia or diabetes are met, manage them per standard medical guidance — do not assume "review in three months" is treatment.

One adherence reality worth knowing: visible metabolic deterioration — a rising weight, a diabetes diagnosis — is a leading reason patients discontinue antipsychotics themselves, and discontinuation feeds relapse and readmission. Monitoring is therefore also an adherence intervention: catching drift early and acting on it preserves the patient's trust in the prescription.

How metabolic monitoring is examined

Examiners rarely ask for a raw schedule dump — they build a vignette around a missed baseline, a wrong frequency, or a risk-ranking error. Typical framings:

  • A patient starts olanzapine; when do you check glucose? Baseline, 12 weeks, then at least annually — sooner if weight rises or symptoms appear.
  • Which drug in this list is least metabolically risky? Rank by tier; aripiprazole and ziprasidone are the usual correct answers.
  • What weight change should trigger action? ≥5% at one month or ≥10% at any point.
  • A prolactin question disguised as a metabolic one. The two monitoring streams run in parallel — metabolic labs for all patients on antipsychotics, prolactin only when symptomatic or on high-risk agents.

If you want the schedule drilled across repeated recall, Preppsy's 2,100+ concept library has structured notes on antipsychotic monitoring with the thresholds attached to each parameter.

Frequently asked questions

What metabolic monitoring do patients on antipsychotics need before starting?

Baseline weight and BMI, waist circumference, blood pressure, fasting glucose or HbA1c, and a full lipid profile — recorded before the first dose. Without a baseline, later readings cannot be interpreted: "weight is stable" is meaningless without a starting point, and pre-existing dyslipidaemia or pre-diabetes will otherwise be attributed to the drug months later. Prolactin and relevant physical parameters are assessed separately as clinically indicated.

How often should weight and glucose be checked on antipsychotics?

Weight and BMI should be checked at least monthly for the first three months (some services check weekly in the first month on high-risk drugs) and at least every three months thereafter. Fasting glucose or HbA1c is checked at baseline, around 12 weeks after starting or a significant dose change, and at least annually — more often if weight rises. Always align exact intervals with your local guideline, such as NICE NG114, as schedules are periodically updated.

Which antipsychotics carry the highest metabolic risk?

Clozapine and olanzapine carry the highest risk of weight gain, new-onset diabetes and dyslipidaemia, with quetiapine and chlorpromazine in the upper ranges. Risperidone and paliperidone are intermediate for metabolic effects (their main monitoring issue is prolactin). Aripiprazole, ziprasidone and lurasidone have the most favourable metabolic profiles and are preferred when metabolic risk is the dominant prescribing concern.

What should you do when a patient gains weight on an antipsychotic?

Act at the intervention threshold: 5% weight gain from baseline within the first month, or 10% at any time. Start structured lifestyle support immediately, consider metformin when glucose or weight trajectory is unfavourable, and reassess the antipsychotic choice — a switch to a lower-risk agent is reasonable if metabolic deterioration continues, balanced against relapse risk. Once diabetes or dyslipidaemia criteria are met, treat them to standard medical thresholds rather than waiting for the next scheduled review.

Key takeaways

  • Baseline before dose one: weight/BMI, waist, BP, glucose or HbA1c, lipids — no baseline means no interpretable data.
  • Fixed-interval schedule: weight at least monthly to 12 weeks then quarterly; glucose and lipids at baseline, 12 weeks, then annually.
  • Intervene at 5%/10%: weight gain thresholds trigger lifestyle action, metformin consideration, or a switch discussion.
  • Know the risk tiers: clozapine/olanzapine highest; aripiprazole/ziprasidone/lurasidone lowest.
  • Metabolic deterioration threatens adherence — catching drift early protects both health and willingness to stay on treatment.
  • Two parallel streams: metabolic monitoring for everyone; prolactin monitoring only when indicated.

Build your monitoring recall into a structured plan with RANZCP exam preparation, where pharmacology schedules and metabolic safety are recurring clinical-vignette material.

Cover image: “Metabolic Monitoring on Antipsychotics (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.